Compounds having activity in correcting mutant-CFTR processing and uses thereof
View Patent ↗The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.
1. A pharmaceutical composition comprising a compound of formula (IV):
wherein R 1 is a alkyl group and R 2 is a substituted or unsubstituted phenyl group; or a pharmaceutically acceptable derivative thereof, as an individual stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 , wherein the composition further comprises at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.
3. The pharmaceutical composition of claim 1 , wherein the composition does not contain detectable dimethyl sulfoxide.
4. The pharmaceutical composition of claim 1 , wherein R 1 is a methyl group.
5. The pharmaceutical composition of claim 1 , wherein R 2 is chosen from a 3-(nitro)phenyl group, a 2-methoxyphenyl, a 2-ethoxyphenyl, a 1-phenylethyl-1-one group, or a 3-chloro-6-methoxyphenyl group.
6. The pharmaceutical composition of claim 1 , wherein the compound is chosen from:
7. A method of treating a subject having a condition associated with mutant-CFTR, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 1 .
8. The method of claim 7 , wherein said condition is cystic fibrosis.
9. The method of claim 7 , wherein the subject, after treatment, has a decrease in mucous or bacterial titer in their lungs, a decrease in coughing or wheezing, a decrease in pancreatic insufficiency, or a decrease in electrolyte levels in their sweat.
10. The method of claim 7 , wherein said subject is a non-human animal.
11. The method of claim 7 , wherein the animal is a mammal.
12. The method of claim 7 , wherein the mutant-CFTR is a ΔF508-CFTR.